A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Atavistik Bio, Inc
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Hoffmann-La Roche
Genmab
Duke University
AstraZeneca
Poseida Therapeutics, Inc.
AstraZeneca
University of Kansas Medical Center
Amgen
AstraZeneca
Brigham and Women's Hospital
Varian, a Siemens Healthineers Company
City of Hope Medical Center
Assistance Publique - Hôpitaux de Paris
BicycleTx Limited
SystImmune Inc.
Vanderbilt-Ingram Cancer Center
Masonic Cancer Center, University of Minnesota
Jonsson Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
University of Alabama at Birmingham
University of Chicago
Eli Lilly and Company
Klus Pharma Inc.
Tempus AI
N.N. Petrov National Medical Research Center of Oncology
Memorial Sloan Kettering Cancer Center
Cybrexa Therapeutics
Carisma Therapeutics Inc
UNICANCER
The University of Texas Health Science Center, Houston
University of Toronto
Shanghai PerHum Therapeutics Co., Ltd.
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Baltimore VA Medical Center
Comprehensive Support Project for Oncology Research
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NGM Biopharmaceuticals, Inc